Interpreting cancer genomes using systematic host network perturbations by tumour virus proteins

Article metrics

Abstract

Genotypic differences greatly influence susceptibility and resistance to disease. Understanding genotype–phenotype relationships requires that phenotypes be viewed as manifestations of network properties, rather than simply as the result of individual genomic variations1. Genome sequencing efforts have identified numerous germline mutations, and large numbers of somatic genomic alterations, associated with a predisposition to cancer2. However, it remains difficult to distinguish background, or ‘passenger’, cancer mutations from causal, or ‘driver’, mutations in these data sets. Human viruses intrinsically depend on their host cell during the course of infection and can elicit pathological phenotypes similar to those arising from mutations3. Here we test the hypothesis that genomic variations and tumour viruses may cause cancer through related mechanisms, by systematically examining host interactome and transcriptome network perturbations caused by DNA tumour virus proteins. The resulting integrated viral perturbation data reflects rewiring of the host cell networks, and highlights pathways, such as Notch signalling and apoptosis, that go awry in cancer. We show that systematic analyses of host targets of viral proteins can identify cancer genes with a success rate on a par with their identification through functional genomics and large-scale cataloguing of tumour mutations. Together, these complementary approaches increase the specificity of cancer gene identification. Combining systems-level studies of pathogen-encoded gene products with genomic approaches will facilitate the prioritization of cancer-causing driver genes to advance the understanding of the genetic basis of human cancer.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Figure 1: Systematic mapping of binary interactions and protein complex associations between viral and host proteins.
Figure 2: Transcriptome perturbations induced by viral protein expression.
Figure 3: The Notch pathway is targeted by multiple DNA tumour virus proteins.
Figure 4: Interpreting cancer genomes with the use of virus–host network models.

Accession codes

Primary accessions

Gene Expression Omnibus

Data deposits

Microarray data were deposited in the Gene Expression Omnibus database under accession number GSE38467.

References

  1. 1

    Vidal, M., Cusick, M. E. & Barabási, A. L. Interactome networks and human disease. Cell 144, 986–998 (2011)

  2. 2

    Stratton, M. R. Exploring the genomes of cancer cells: progress and promise. Science 331, 1553–1558 (2011)

  3. 3

    Gulbahce, N. et al. Viral perturbations of host networks reflect disease etiology. PLOS Comput. Biol. 8, e1002531 (2012)

  4. 4

    Calderwood, M. A. et al. Epstein–Barr virus and virus human protein interaction maps. Proc. Natl Acad. Sci. USA 104, 7606–7611 (2007)

  5. 5

    Shapira, S. D. et al. A physical and regulatory map of host–influenza interactions reveals pathways in H1N1 infection. Cell 139, 1255–1267 (2009)

  6. 6

    Howley, P. M. & Livingston, D. M. Small DNA tumor viruses: large contributors to biomedical sciences. Virology 384, 256–259 (2009)

  7. 7

    Foxman, E. F. & Iwasaki, A. Genome–virome interactions: examining the role of common viral infections in complex disease. Nature Rev. Microbiol. 9, 254–264 (2011)

  8. 8

    Editorial. What is the Human Variome Project? Nature Genet. 39, 423 (2007)

  9. 9

    Dreze, M. et al. High-quality binary interactome mapping. Methods Enzymol. 470, 281–315 (2010)

  10. 10

    Lamesch, P. et al. hORFeome v3.1: a resource of human open reading frames representing over 10,000 human genes. Genomics 89, 307–315 (2007)

  11. 11

    Yu, H. et al. Next-generation sequencing to generate interactome datasets. Nature Methods 8, 478–480 (2011)

  12. 12

    Zhou, F. et al. Online nanoflow RP-RP-MS reveals dynamics of multicomponent Ku complex in response to DNA damage. J. Proteome Res. 9, 6242–6255 (2010)

  13. 13

    Brimer, N., Lyons, C. & Vande Pol, S. B. Association of E6AP (UBE3A) with human papillomavirus type 11 E6 protein. Virology 358, 303–310 (2007)

  14. 14

    Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646–674 (2011)

  15. 15

    Fujita, K., Maeda, D., Xiao, Q. & Srinivasula, S. M. Nrf2-mediated induction of p62 controls Toll-like receptor-4-driven aggresome-like induced structure formation and autophagic degradation. Proc. Natl Acad. Sci. USA 108, 1427–1432 (2011)

  16. 16

    Wu, Z. H., Shi, Y., Tibbetts, R. S. & Miyamoto, S. Molecular linkage between the kinase ATM and NFκB signaling in response to genotoxic stimuli. Science 311, 1141–1146 (2006)

  17. 17

    Tanaka, N. et al. Cooperation of the tumour suppressors IRF-1 and p53 in response to DNA damage. Nature 382, 816–818 (1996)

  18. 18

    Ranganathan, P., Weaver, K. L. & Capobianco, A. J. Notch signalling in solid tumours: a little bit of everything but not all the time. Nature Rev. Cancer 11, 338–351 (2011)

  19. 19

    Proweller, A. et al. Impaired Notch signaling promotes de novo squamous cell carcinoma formation. Cancer Res. 66, 7438–7444 (2006)

  20. 20

    Marcuzzi, G. P. et al. Spontaneous tumour development in human papillomavirus type 8 E6 transgenic mice and rapid induction by UV-light exposure and wounding. J. Gen. Virol. 90, 2855–2864 (2009)

  21. 21

    Brimer, N., Lyons, C., Wallberg, A. E. & Vande Pol, S. B. Cutaneous papillomavirus E6 oncoproteins associate with MAML1 to repress transactivation and NOTCH signaling. Oncogene 10.1038/onc.2011.589 (16 January 2012)

  22. 22

    Calderwood, M. A. et al. Epstein–Barr virus nuclear protein 3C binds to the N-terminal (NTD) and beta trefoil domains (BTD) of RBP/CSL; only the NTD interaction is essential for lymphoblastoid cell growth. Virology 414, 19–25 (2011)

  23. 23

    Klinakis, A. et al. A novel tumour-suppressor function for the Notch pathway in myeloid leukaemia. Nature 473, 230–233 (2011)

  24. 24

    Forbes, S. A. et al. COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res. 39, D945–D950 (2011)

  25. 25

    Copeland, N. G. & Jenkins, N. A. Harnessing transposons for cancer gene discovery. Nature Rev. Cancer 10, 696–706 (2010)

  26. 26

    Adzhubei, I. A. et al. A method and server for predicting damaging missense mutations. Nature Methods 7, 248–249 (2010)

  27. 27

    Beroukhim, R. et al. The landscape of somatic copy-number alteration across human cancers. Nature 463, 899–905 (2010)

  28. 28

    Manolio, T. A. Genomewide association studies and assessment of the risk of disease. N. Engl. J. Med. 363, 166–176 (2010)

  29. 29

    Berriz, G. F., King, O. D., Bryant, B., Sander, C. & Roth, F. P. Characterizing gene sets with FuncAssociate. Bioinformatics 19, 2502–2504 (2003)

Download references

Acknowledgements

We thank members of the Center for Cancer Systems Biology (CCSB) and J. Aster, M. Meyerson, W. Kaelin, G. Superti-Furga and S. Sunyaev for discussions, and J.W. Harper, W. Hahn, P. Howley, Y. Jacob, M. Imperiale, I. Koralnik, H. Pfister and D. Wang for reagents. This work was primarily supported by Center of Excellence in Genomic Science (CEGS) grant P50HG004233 from the National Human Genome Research Institute (NHGRI) of the National Institutes of Health (NIH) awarded to M.V. (principal investigator), A.-L.B., J.A.D., E.K., J.A.M., K.M., J.Q. and F.P.R. Additional funding included Institute Sponsored Research funds from the Dana-Farber Cancer Institute Strategic Initiative to M.V.; NIH grants R01HG001715 to M.V., D.E.H. and F.P.R.; R01CA093804, R01CA063113 and P01CA050661 to J.A.D.; R01CA081135, R01CA066980 and U01CA141583 to K.M.; R01CA131354, R01CA047006 and R01CA085180 to E.K.; T32HL007208 and K08HL098361 to R.C.D.; K08CA122833 to R.B.; F32GM095284 and K25HG006031 to M.P.; Canada Excellence Research Chairs (CERC) Program, Canadian Institute for Advanced Research Fellowship and Ontario Research Fund to F.P.R.; and James S. McDonnell Foundation grant 220020084 to A.-L.B. M.V. is a ‘Chercheur Qualifié Honoraire’ from the Fonds de la Recherche Scientifique (Wallonia-Brussels Federation, Belgium).

Author information

O.R.-R., G.A., M.A.C., M.G., A.D., Ma.T., F.A., D.B., A.A.C., J.C., M.C., M.D., M.C.F., S.B.F., R.F., B.K.G., A.M.H., R.J., A.K., L.L., R.R., J.M.S., S.W., J.R.-C. and E.J. performed experiments or contributed new reagents. R.C.D., M.P., G.A., T.R., M.A., S.P., A.-R.C., C.F., N.G., T.H., J.C.M., T.R.P., S.R., Y.S., S.S., Mu.T. and J.T.W. performed computational analysis. O.R.-R., R.C.D., M.P., G.A., M.A.C., T.R., M.E.C., D.E.H., K.M., J.A.M., F.P.R., J.A.D. and M.V. wrote the manuscript. A.-L.B., R.B., E.K., M.E.C., D.E.H., K.M., J.A.M., J.Q., F.P.R., J.A.D. and M.V. designed or advised research. M.A.C., T.R., M.G., A.D., M.A., Ma.T. and S.P. contributed equally and should be considered joint second authors; D.E.H., K.M., J.A.M., J.Q., F.P.R., J.A.D. and M.V should be considered joint senior authors; additional co-authors are listed alphabetically.

Correspondence to Jarrod A. Marto or John Quackenbush or Frederick P. Roth or James A. DeCaprio or Marc Vidal.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Supplementary information

Supplementary Information

This file contains Supplementary Figures 1-22, legends for Supplementary Tables 1-22 and Supplementary Text and additional references. (PDF 4812 kb)

Supplementary Data

This zipped file contains Supplementary Tables 1-22. (ZIP 4696 kb)

PowerPoint slides

Rights and permissions

Reprints and Permissions

About this article

Further reading

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.